Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.

Journal: Journal of hepatology
PMID:

Abstract

BACKGROUND & AIMS: Intra and inter-pathologist variability poses a significant challenge in metabolic dysfunction-associated steatohepatitis (MASH) biopsy evaluation, leading to suboptimal selection of patients and confounded assessment of histological response in clinical trials. We evaluated the utility of an artificial intelligence (AI) digital pathology (DP) platform to help pathologists improve the reliability of fibrosis staging.

Authors

  • Desiree Abdurrachim
    Quantitative Biosciences, MSD, Singapore. Electronic address: desiree.abdurrachim@msd.com.
  • Serene Lek
    HistoIndex Pte. Ltd., Singapore.
  • Charlene Zhi Lin Ong
    Quantitative Biosciences, MSD, Singapore.
  • Chun Kit Wong
    Quantitative Biosciences, MSD, Singapore.
  • Yongqi Zhou
    Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New Area, Shanghai 201210, China.
  • Aileen Wee
    Department of Pathology, National University Hospital, Singapore.
  • Gwyneth Soon
    Department of Pathology, National University Hospital, Singapore.
  • Timothy J Kendall
    Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, United Kingdom.
  • Michael O Idowu
    Department of Pathology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
  • Christopher Hendra
    Quantitative Biosciences, MSD, Singapore.
  • Ashmita Saigal
    Cardiometabolic Diseases, Merck & Co., Inc., South San Francisco, CA, USA.
  • Radha Krishnan
    Global Clinical Trial Organization, MSD (UK) Limited, London, UK.
  • Elaine Chng
    HistoIndex Pte. Ltd., Singapore.
  • Dean Tai
    HistoIndex Pte Ltd, Singapore.
  • Gideon Ho
    HistoIndex Pte. Ltd., Singapore.
  • Thomas Forest
    Non-clinical Drug Safety, Merck & Co., Inc., West Point, PA, USA.
  • Annaswamy Raji
    Global Clinical Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Saswata Talukdar
    Cardiometabolic Diseases, Merck & Co., Inc., South San Francisco, CA, USA.
  • Chih-Liang Chin
    Cardiometabolic Diseases, Merck & Co., Inc., South San Francisco, CA, USA.
  • Richard Baumgartner
    Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
  • Samuel S Engel
    Merck & Co., Inc., Rahway, NJ, USA.
  • Asad Abu Bakar Ali
    Quantitative Biosciences, MSD, Singapore.
  • David E Kleiner
    Laboratory of Pathology National Cancer Institute, National Institutes of Health Bethesda MD.
  • Arun J Sanyal
    Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.